Oxford BioTherapeutics Outlicenses Novel Antibody to Genmab for Immuno-Oncology
- OBT to receive an up front and additional development & regulatory milestones along with royalty. Genmab will be responsible for the future development and commercialization of any products
- Under the commercial license agreement with OBT, Genmab gets the rights to an OBT's novel, pre-clinical immuno-oncology Ab & also obtains an exclusive right to develop & commercialize novel Abs therapies using OBT's novel IO Ab. The target was identified utilizing Oxford BioTherapeutics' OGAP drug discovery platform which integrates clinical, experimental, expression data & proteome databases
- In a US clinical trial, OBT's OBT076 began expanding in 2021 for advanced or refractory solid tumors, incl. gastric cancer & other indication
Ref: PRNewswire | Image: Genmab
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].